Comparison of systematic and narrative reviews: The example of the atypical antipsychotics

Epidemiologia e Psichiatria Sociale

Volumn 12, Issue 3, 2003, Pages 146-153

  Cipriani, Andrea ^b   Geddes, John ^a  

^a WARNEFORD HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

CLINICAL RESEARCH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MEDICAL RESEARCH; MENTAL DISEASE; META ANALYSIS; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 0142137105     PISSN: 1121189X     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1121189X00002918     Document Type: Editorial

References (34)

1. Altman D.G. & Bland J.M. (1999). Statistics notes. Treatment allocation in controlled trials: why randomise? British Medical Journal 318, 1209.
2. Altman D.G. & Gardner M.J. (1992). Confidence intervals for research findings. British Journal of Obstetrics and Gynaecology 99, 90-91.
3. Antman E.M., Lau J., Kupelnick B., Mosteller F. & Chalmers T.C. (1992). A comparison of results of meta-analyses of randomized control trials and recommendations of clinical experts. Treatments for myocardial infarction. Journal of the American Medical Association 268, 240-248.
4. Campbell M., Young P.I., Bateman D.N., Smith J.M. & Thomas S.H. (1999). The use of atypical antipsychotics in the management of schizophrenia. British Journal of Clinical Pharmacology 41, 13-22.
5. Carney S.M. & Geddes J.R. (2002). Systematic Reviews Meta-analyses. Evidence in Mental Health Care. Brunner Routledge: Hove.
6. Cochrane Collaboration (1995). Cochrane Collaboration Handbook. Updated 1995. Cochrane Collaboration: Oxford.
7. Davis J. & Chen N. (2002). Clinical profile of an atypical antipsychotic: risperidone. Schizophrenia Bulletin 28, 43-61.
8. Detsky A.S., Naylor C.D., O'Rourke K., McGeer A.J. & L'Abbe K.A. (1992). Incorporating variations in the quality of individual randomised trials into meta-analysis. Journal of Clinical Epidemiology 45, 255-265.
9. Duggan L., Fenton M., Dardennes R.M., El-Dosoky A. & Indran S. (2000). Olanzapine for schizophrenia. Cochrane Library Issue 4.
10. Egger M. & Smith G.D. (1998). Bias in location and selection of studies. British Medical Journal 316, 61-66.
11. Freemantle N. (2001). Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic? British Medical Journal 322, 989-991.
12. Geddes J.R., Wilczynski N., Reynolds S., Szatmari P. & Streiner D.L. (1999). Evidence-based mental health - the first year. Evidence-Based Mental Health 2, 3-5.
13. Geddes J.R., Freemantle N., Harrison P.J. & Bebbington P.E. (2000). Atypical antipsychotics in the treatment of schizophrenia: systematic review and meta-regression analysis. British Medical Journal 321, 1371-1376.
14. Gilbody S.M. & Song F. (2000). Publication bias and the integrity of psychiatry research. Psychological Medicine 30, 253-258.
15. Hopayian K. (2001). The need for caution in interpreting high quality systematic reviews. British Medical Journal 323, 681-684.
16. Irwig L., Tosteson A.N., Gatsonis C., Lau J., Colditz G., Chalmers T.C. & Mosteller F. (1994). Guidelines for meta-analyses evaluating diagnostic tests. Annals of Internal Medicine 120, 667-676.
17. Johnson A.L. (1983). Clinical trials in psychiatry. Psychological Medicine 13, 1-8.
18. Kane J. (1999). Olanzapine in the long-term treatment of schizophrenia. In Focus on Schizophrenia (ed. G.D. Tollefson), British Journal of Psychiatry, Suppl. No. 37, vol. 174, pp. 26-29.
19. Leucht S., Pitschel-Walz G., Abraham D. & Kissling W. (1999). Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research 35, 51-68.
20. Marder S.R. (1999). Antipsychotic drugs and relapse prevention. Schizophrenia Research, Suppl. No. 1, vol. 35, pp. 87-92.
21. Mulrow C.D. (1987). The medical review article: state of the science. Annals of Internal Medicine 106, 485-488.
22. Mulrow C.D. (1994). Rationale for systematic reviews. British Medical Journal 309, 597-599.
23. Mulrow C.D., Williams J.W.Jr., Gerety M.B., Ramirez G., Montiel O.M. & Kerber C. (1995). Case-finding instruments for depression in primary care settings. Annals of Internal Medicine 122, 913-921.
24. Oxman A.D. (1994). Systematic Reviews: Checklists for review articles. British Medical Journal 309, 648-651.
25. Sackett D.L. & Wennberg J.E. (1997). Choosing the best research design for each question. British Medical Journal 315, 1636.
26. Stahl S.M. (1999). Selecting an atypical antipsychotic by combining clinical experience with guidelines from clinical trials. In What Makes an Antipsychotic Atypical? (ed. S.M. Stahl), Journal of Clinical Psychiatry, Suppl. No. 10, vol. 60, pp. 31-41.
27. Stephenson C.M.E. & Pilowsky L.S. (1999). Psychopharmacology of olanzapine. A review. In New Antipsychotics. Preclinical and Clinical Comparison (ed. R. Kerwin), British Journal of Psychiatry, Suppl. No. 38, vol. 174, pp. 52-58.
28. Stewart L.A. & Clarke M.J. (1995). Practical methodology of meta-analyses (overviews) using updated individual patient data. Cochrane Working Group. Statistics in Medicine 14, 2057-2079.
29. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., Moher D., Becker B.J., Sipe T.A. & Thacker S.B. (2000). Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. Journal of the American Medical Association 283, 2008-2012.
30. Tandon R., Milner K. & Jibson M.D. (1999). Antipsychotics from theory to practice: integrating clinical and basic data. In Advances in the Treatment of Psychosis in the Elderly (ed. P.N. Tariot), Journal of Clinical Psychiatry, Suppl. No.8, vol. 60, pp. 21-28.
31. Thompson S.G. (1994). Why sources of heterogeneity in meta-analysis should be investigated. British Medical Journal 309, 1351-1355.
32. Thornley B. & Adams C. (1998). Content and quality of 2000 controlled trials in schizophrenia over 50 years. British Medical Journal 317, 1181-1184.
33. Tollefson G.D. & Kuntz A.J. (1999). Review of recent clinical studies with olanzapine. In Focus on Schizophrenia (ed. G.D. Tollefson), British Journal of Psychiatry, Suppl. No. 37, vol. 174, pp. 30-35.
34. Waraich P.S., Adams C.E., Roque M., Hamill K.M. & Marti J. (2002). Haloperidol dose for the acute phase of schizophrenia. Cochrane Library Issue 4.